This systematic review and meta‐analysis analysed 62 studies, with a total of 66,232 patients at a mean follow‐up of 43.5 weeks, to evaluate the rates of pancreatitis and pancreatic cancer among patients taking GLP‐1 RAs. This evidence concerns the gene GLP1R and familial pancreatic carcinoma.